Jefferies Names Top Tobacco Stocks Amid Nicotine Pouch Competition

Velo drove category growth with volume +197.2% and value +247.2% in March, adding 14.1M units (vs 13.5M in Feb) and lifting price/unit to $5.20 from $5.10. ZYN’s volume growth slowed to 2.4% in March (from 7.1% in Feb) while price remained high at $6.80; Altria’s on! volumes fell 15.5% and value fell 5.2% with price recovering to $4.60 (52‑week avg $3.00). Zone improved sequentially (vol +31.3%, value +39.9%) but Jefferies sees limited US challenger potential; overall Jefferies flags nicotine pouches as a key growth area amid mixed company-level outcomes.

Analysis

The oral-nicotine shift is increasingly a scale and distribution game rather than a pure-product innovation race; brands that control retail shelf economics, COGS on pouches, and bespoke trade promotion mechanics will convert trial into durable share. That favors incumbents with broad tobacco retail relationships and flexible co-manufacturing footprints, creating a widening moat: smaller challengers can drive short-term volatility in velocity, but they struggle to hold price and rarify distribution without subsidized promos.

Second-order supply and cost dynamics matter: packaging and polymer suppliers, nicotine intermediate manufacturers, and co-packers have limited incremental capacity, so rapid SKU proliferation can raise lead times and force either promotional overhangs or margin erosion if brands accelerate fill rates. Regulatory tail risks (FDA marketing denial orders, synthetic-nicotine redefinitions, flavor restrictions) create binary outcomes over 3–18 months — a market-friendly outcome preserves high-margin growth, while adverse rulings compress multiples materially and trigger consolidation.

Given the set-up, the near-term battle will be who defends premium pricing versus who buys volume through trade spend; that determines margin trajectory and capital allocation (buybacks vs. M&A). Watch monthly POS trends and promotional depth as the earliest signal — a sustained increase in promotional incidence over two consecutive months is the fastest harbinger of a price-led race to the bottom with 3–6 month lag to margin impact.

Key Decisions for Investors

• Long BTI (British American Tobacco) equity or a 6–12 month call spread exposure: enter on any <5% pullback vs the 20-day average. Thesis: scale + retail economics will keep pricing premium intact. Target +25–40% absolute upside over 6–12 months; stop at -12% (or roll into longer-dated calls).
• Pair trade: Long BTI / Short MO (Altria) equal notional for 6–9 months. Rationale: BTI captures share gains and pricing optionality while MO risks premium not sustaining and greater exposure to on! volume softness. Target relative outperformance of 30% (i.e., BTI +20% / MO -10%); hard stop if spread tightens by 10% in two weeks.
• Tactical hedge: Buy 9–12 month out-of-the-money puts on MO (protective) sized to cover short position or portfolio exposure — use 10–15% delta puts as insurance. Cost should be <2–3% of notional for a reasonable tail hedge; this pays off if regulatory or pricing shocks hit within 6–12 months.
• Conservative defensive: Accumulate PM on dips for 12–18 months as a carry/defensive play, stepping in on >8% drawdowns. Risk/reward: modest upside (15–25%) vs lower downside volatility; exit if promotional intensity rises two months running or if FDA actions increase regulatory risk premium.